Sun Pharma Advanced Research Company Ltd. (SPARC) announced that it has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for US $195 million upon the closing of the transaction. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Official Regulatory Filing

The company filed the official disclosure with the National Stock Exchange of India Ltd. and BSE Limited through a formal communication dated April 30, 2026. The filing reference SPARC/Sec/SE/2026-27/05 was signed by Kajal Damania, Company Secretary and Compliance Officer.

Transaction Overview

The PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby®, which is indicated for the treatment of neonatal seizures. SEZABY® is a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium powder for injection.

Strategic Impact

Anil Raghavan, CEO of SPARC, stated that the sale of the PRV will enable the company to accelerate the development of its pipeline assets and strengthen its external innovation strategy, which has already delivered multiple additions to its portfolio.

The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Stifel acted as the exclusive financial advisor to SPARC with respect to this transaction.

Regulatory Compliance Details

As per the SEBI disclosure requirements, the transaction details confirm this is not a related party transaction and the company holds no shareholding in the counterparty.

About Sun Pharma Advanced Research

Sun Pharma Advanced Research Company Ltd. is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. The company consistently aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world.

Source: None/Company/INE232I01014/9dee41b62db44ca0.pdf

Dilip S. Shanghvi, promoter of sun pharma advanced research co , has filed a regulatory declaration with the National Stock Exchange and BSE Limited, confirming no encumbrance on company shares as of March 31, 2026. The declaration was submitted on April 02, 2026, in compliance with SEBI regulations governing substantial acquisitions and takeovers.

Regulatory Compliance Declaration

The declaration was made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to disclose any encumbrances created on shares of the target company during specified periods.

Share Encumbrance Status

Shanghvi confirmed that as of March 31, 2026, neither he nor the promoter group and persons acting in concert have created any encumbrance, directly or indirectly, on the shares of Sun Pharma Advanced Research Company Limited. The declaration specifically noted that no new encumbrances were made other than those already disclosed during the financial year.

Stock Exchange Communication

The formal declaration was addressed to both major Indian stock exchanges where the company's shares are listed. The communication was sent to the National Stock Exchange of India Limited and BSE Limited, ensuring compliance with disclosure requirements across all trading platforms.

The declaration serves as an important transparency measure, providing investors and regulatory authorities with current information about promoter shareholding patterns and any potential encumbrances that could affect share ownership or voting rights.